Bayer AG at JPMorgan Healthcare Conference Transcript
()-
Welcome to the Bio session at the 2026 JPMorgan Healthcare Conference. I'm Richard Vosser, European pharma analyst with JPMorgan. It's my great pleasure to introduce from the Bayer Healthcare business, the pharma business, Stefan Oelrich. Before I hand over to Stefan to give a presentation, I just remind you that we can take your questions afterwards if you put your hand up or you can submit them on the portal. Stefan, welcome to the conference.
Thank you, Richard, and hi, everyone, and good morning. Really excited to give you an update on where we stand in our progress with Bayer Pharma and I'll jump right into it. And those that have followed me last year, you will remember maybe some of this. I'm happy to share that we're making excellent progress along the way. And it's really a new company emerging since then, both on renewing our top line, where we've seen clear
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
